The settlement will resolve litigation of around 11,000 claims against the company, plaintiff attorneys from Seeger Weiss LLP and Douglas & London P.C confirmed to The Hill. Many of the claims alleged that the two drugs led to kidney injuries that over time could evolve into end-stage renal disease.
Still, AstraZeneca asserts that it settled to avoid continuous litigation and that “these claims are without merit and admits no wrongdoing in the settlement agreement,” according to the release.
One additional case is still pending related to these consumer product claims and is set to go to trial April 15, 2024.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
